LSD's Full Circle Trip, Nears Pharma Comeback

LSD is framed as nearing a pharma comeback as Definium Therapeutics advances LSD-based treatments in phase 3 trials for general anxiety and major depression, and for autism. The report traces LSD’s history from its early 1940s medical origins as Delysid, developed and marketed by Sandoz, to its end of production in 1965 due to rising recreational use, then to the 1970 U.S. Schedule 1 law after backlash. It highlights Definium’s “Rerouting Minds” awareness campaign and rebranding from MindMed to Definium, positioning the effort as building credibility with healthcare providers and the public. The piece also links regulatory pathway expectations to FDA approval and potential DEA scheduling changes, arguing that renewed research acceptance could help bring LSD back into clinical psychiatry and medical settings.